Disease Overview：Teratoma（TER）
Teratoma is a germ cell tumor composed of tissues derived from more than one embryonic germ layer—ectoderm, mesoderm, and endoderm—often containing elements such as hair, teeth, bone, or neural tissue. While most commonly diagnosed in the ovaries or testes, mediastinal, retroperitoneal, and sacrococcygeal locations also occur. In males, testicular teratomas are typically part of mixed non-seminomatous germ cell tumors (NSGCTs) and carry significant malignant potential, necessitating prompt staging with serum tumor markers (AFP, β-hCG, LDH), contrast-enhanced CT/MRI, and definitive management via radical inguinal orchiectomy followed by risk-stratified adjuvant therapy—including surveillance, chemotherapy (e.g., bleomycin-etoposide-cisplatin), or retroperitoneal lymph node dissection (RPLND). Accurate histopathological classification (mature vs. immature, teratoma with somatic-type malignancy) directly informs prognosis and therapeutic decisions.
China offers distinct advantages for teratoma management: leading uro-oncology centers—such as Peking University First Hospital and Fudan University Shanghai Cancer Center—combine deep expertise in germ cell tumor protocols with access to next-generation sequencing, intraoperative neuromonitoring during RPLND, and high-precision radiotherapy platforms like TrueBeam STx. Clinical outcomes align with international benchmarks: 5-year overall survival exceeds 95% for stage I disease and remains >80% even in advanced cases managed with multimodal regimens. Treatment costs are typically 40–60% lower than in the US or Western Europe, without compromising evidence-based standards. As a dedicated medical tourism agency, we facilitate seamless care for international patients—vetting JCI-accredited hospitals, coordinating appointments with certified urologic oncologists, providing itemized, transparent pricing in advance, and offering end-to-end support including visa assistance, medical translation, accommodation, and post-treatment follow-up coordination.
Teratoma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Teratoma (Urology/Andrology)
I. Non-Surgical / Conservative Management *Indicated only for asymptomatic, small (<2 cm), non-growing, histologically benign-appearing teratomas confirmed by MRI + tumor markers (AFP, β-hCG, LDH), with no testicular enlargement or pain.*
- •Monitoring Protocol (6–12-month intervals):
- Serum AFP + β-hCG + LDH: $38 - Clinical exam + andrology consultation: $22 - Annual total (Tier 1 public hospital): $105–$125 - Tier 2 (municipal key hospital): $135–$165 - Tier 3 (national referral center): $180–$220
II. Surgical Treatment (Radical Inguinal Orchiectomy) *Standard of care for all palpable, growing, marker-elevated, or symptomatic testicular teratomas — regardless of age or presumed benignity.*
- •Eligibility: Confirmed or highly suspected teratoma on ultrasound/MRI; elevated tumor markers; testicular mass >1.5 cm; pain/swelling; infertility workup finding.
- •Preoperative Workup (mandatory):
- ECG + pulmonary function test (if >60 yrs or comorbidities): $78 - Blood typing, coagulation panel, liver/kidney function: $42 - Total pre-op cost: $315
- •Surgery Fees (all-inclusive: surgeon, anesthesia, OR, 1-day admission):
- Tier 2 (municipal 3A): $1,850–$2,200 - Tier 3 (national 3A, e.g., PUMCH, Huashan): $2,400–$2,950
- •*Note:* Retroperitoneal lymph node dissection (RPLND) is *not* indicated for pure teratoma without metastasis; reserved for stage II+ disease post-orchiectomy.
- •Bilateral synchronous teratomas (rare): Testis-sparing surgery (microsurgical enucleation) + intraoperative frozen section. Requires high-volume andrology center. Fee range: $3,100–$4,300, including extended OR time, pathology rush fee, and 2-day admission.
- •Post-chemotherapy residual mass (>1 cm): Delayed RPLND. Pre-op PET-CT required ($420); RPLND fee: $3,800–$5,200 (Tier 3 only).
- •Teratoma with malignant transformation (e.g., embryonal carcinoma component): Oncology-directed multimodal therapy; costs governed by chemotherapy regimen (cisplatin-based: $1,200–$2,800/cycle, 3–4 cycles).
- •<35 years, asymptomatic <1.5 cm, normal markers: Conservative monitoring (Tier 1: $105/year) — *optimal for low-risk young men prioritizing fertility preservation*.
- •Any age, palpable mass or elevated AFP/β-hCG: Immediate radical orchiectomy at Tier 2 center ($1,850–$2,200) — *gold standard; balances expertise, cost, and timely diagnosis*.
- •>65 years, significant cardiac comorbidity: Pre-op cardiology clearance + optimized anesthesia pathway; choose Tier 2 with integrated geriatric urology (+ $210 pre-op add-on).
- •Residual mass post-chemo or bilateral disease: Refer to national 3A andrology-oncology unit (PUMCH, Fudan UHS) — *essential for microsurgical precision and molecular staging*.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Teratoma Medical Vacation Packages
Curated transparent all-inclusive packages combining Teratoma treatment with China top medical destinations:
